Scientific Advisory Board
David Tuveson, M.D., Ph.D.
Chair of Leap SAB, Director of Research, the Lustgarten Foundation, Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory
David Tuveson is professor and deputy director of the cancer center at Cold Spring Harbor Laboratory. Dr. Tuveson obtained a Bachelor’s Degree in Chemistry at M.I.T. and Medical and Doctoral Degrees at Johns Hopkins. Dr. Tuveson was a medical resident at Brigham and Women’s Hospital and a medical oncology fellow at Dana-Farber/Partners Cancer Care.
During his postdoctoral years in Boston, Dr. Tuveson co-developed KIT inhibitors for gastrointestinal stromal tumors with George Demetri, and created several Kras dependent mouse cancer models with Tyler Jacks. His lab generated the first mouse models of ductal pancreatic cancer at the University of Pennsylvania, and subsequently moved to the University of Cambridge to develop preclinical and clinical therapeutic strategies for pancreatic cancer.
In Cambridge, his lab identified a variety of parameters that limit therapeutic efficacy in pancreatic cancer, including poor drug delivery and survival factors in the microenvironment. These findings are currently undergoing clinical evaluation. Dr. Tuveson now directs the Cancer Therapeutics Initiative at Cold Spring Harbor Laboratory and to serve as director of research for the Lustgarten Foundation. He will continue to practice medical oncology with an adjunct appointment at Memorial Sloan-Kettering Cancer Center. His honors include an award from the Rita Allen Foundation.
Xi He, Ph.D.
Endowed Research Chair, Professor of Neurology, American Cancer Society Research Professor, Boston Children’s Hospital and Harvard Medical School
Xi He received his PhD in 1992 from the University of California, San Diego, where he worked in the laboratory of Michael G. Rosenfeld. He completed a postdoctoral fellowship in 1996 at the National Institutes of Health, under the supervision of Harold E. Varmus.
He was a Pew Scholar in Biomedical Sciences, a Klingenstein Fellow in Neuroscience, a Keck Foundation Distinguished Young Scholar in Medical Research and a Leukemia and Lymphoma Society Scholar. He is a Chang Jiang Guest Professor at the School of Life Science and Technology, Huazhong University of Science and Technology in Wuhan, China, inducted by the Ministry of Education of China.
Xi He is a member of the executive board of the Stem Cell Program at Boston Children's Hospital and a member of the editorial boards of Journal of Biological Chemistry, Journal of Genetics and Genomics and Protein & Cell. He has served and is serving on the Scientific Advisory Boards of institutes of the Chinese Academy of Sciences and of biotechnology companies in the United States, China and Europe.
Carl F. Nathan, M.D.
Professor and Chairman of Department of Microbiology and Immunology at Weill Cornell Medical College
Carl Nathan, M.D., is R.A. Rees Pritchett Professor and chairman of the Department of Microbiology and Immunology at Weill Cornell Medical College and co-chair of the Program in Immunology and Microbial Pathogenesis at Weill Graduate School of Medical Sciences of Cornell University.
A graduate of Harvard College and Harvard Medical School, he trained in internal medicine and oncology at Massachusetts General Hospital, the National Cancer Institute, and Yale before joining the faculty of The Rockefeller University. At Weill Cornell Medical College, he has served as founding director of the Tri-Institutional MD-PhD Program, senior associate dean for research, and acting dean and presently directs the Milstein Program in Chemical Biology of Infectious Disease.
A member of the Institute of Medicine of the National Academy of Sciences, a Fellow of the American Academy of Microbiology, a former Ellison Medical Foundation senior scholar in global infectious diseases and a Trustee of the Hospital for Special Surgery, he also serves as an adviser to the Cambridge University Institute for Medical Research, associate scientific director of the Cancer Research Institute and an editor of the Journal of Experimental Medicine.
Eric P. Winer, M.D.
Senior Vice President and Chief Clinical Strategy Officer; Chief, Division of Women's Cancers, Dana Farber Cancer Institute; Director, Breast Oncology Program, Susan F. Smith Center for Women's Cancers; Thompson Chair in Breast Cancer Research Institute Physician; Professor of Medicine, Harvard Medical School
Dr. Winer received his MD from Yale University in 1983, and later completed training in internal medicine and served as chief resident at Yale-New Haven Hospital. He subsequently was a fellow in hematology-oncology at Duke University Medical Center, and from 1989 to 1997 served on the Duke faculty, where he became codirector of the multidisciplinary breast program. In 1997, he joined Brigham and Women's Hospital and DFCI, where he is director of the Breast Oncology Center.
Dr. Winer is the principal investigator of the Dana-Farber/Harvard Cancer Center NCI SPORE (National Cancer Institute Specialized Program of Research Excellence) in breast cancer. His research group focuses on improving care and quality of life for breast cancer patients through new drug treatments developed in clinical trials. He also co-chairs the Breast Committee in the Alliance for Clinical Trials in Oncology, a national clinical trials network.
Dr. Nixon received his PhD in biochemistry in 1997 from Wake Forest University and later completed his postdoctoral fellowship at Duke University in the laboratory of Dr. Patrick Casey. He joined the Department of Medicine at Duke as an Assistant Professor in 2004 and established the Phase I Biomarker Laboratory. His research focuses on the interrogation of circulating markers found in the blood, pursuing the development of novel biomarkers for immuno-oncology and anti-angiogenic agents.
He is a nationally recognized expert regarding the development of biomarkers and serves as a scientific reviewer for the NCI/NCTN Core Correlative Sciences Committee (CCSC). Within the Alliance cooperative group, he serves as an executive member of the Translational Research Program, vice-chair for GI correlative research, and now serves as co-chair for the newly established Immuno-Oncology Committee. He also serves on the GYN translational science committee for the NRG cooperative group. In addition, he is on the Board of Directors for the Academic and Community Cancer Research United (ACCRU) group and an Advisory Board member for Powering Precision Health.
Dr. Richard Gaynor is currently President and Chief, Research and Development, at BioNTech US. Dr. Gaynor joined Neon Therapeutics in 2016 as President of Research and Development and continued his career there following their merger with BioNTech US. Prior to joining Neon, Dr. Gaynor was Senior Vice President of Global Product Development and Medical Affairs at Lilly Oncology. In total, he spent 15 years in senior roles at Lilly Oncology where he led preclinical and early clinical oncology research and served on key company portfolio review committees. Prior to that he served on the faculty at University of Texas Southwestern Medical School, where he served as the Chief of the Division of Hematology-Oncology and Director of the Simmons Cancer Center. Dr. Gaynor holds an M.D. from the University of Texas Southwestern Medical School and, following his residency in internal medicine there, he completed fellowship training in hematology-oncology at the UCLA School of Medicine where he served on the hematology- oncology faculty. He is the author of nearly 150 publications and serves on the Scientific Advisory Committee for Stand up to Cancer and the Board of Directors of the Damon Runyon Cancer Research Foundation, Alkermes plc. and Infinity Therapeutics.